Treatment of Philadelphia-Positive Acute Lymphoblastic Leukemia

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) historically presented a poor prognosis.
• Limited therapeutic options were available for Ph+ ALL patients.
• Recent advancements have significantly altered the treatment landscape for Ph+ ALL.

Purpose of the Study:

• To review the evolution of treatment strategies for Ph+ ALL.
• To highlight the impact of tyrosine kinase inhibitors (TKIs) and emerging immunotherapies.
• To discuss the role of measurable residual disease (MRD) monitoring in risk stratification.

Main Methods:

• Review of current literature on Ph+ ALL treatment.
• Analysis of the efficacy of TKIs (imatinib, dasatinib, ponatinib).
• Evaluation of immunotherapeutic agents like blinatumomab and CAR T-cell therapy.
• Discussion on the integration of MRD monitoring.

Main Results:

• TKIs have revolutionized frontline therapy, improving remission rates and survival.
• Combined TKI and chemotherapy/corticosteroid regimens offer less toxic options.
• MRD monitoring aids in risk stratification and treatment decisions.
• Immunotherapies (blinatumomab, CAR T-cells) show efficacy in relapsed/refractory and frontline settings.

Conclusions:

• TKIs are the cornerstone of Ph+ ALL treatment.
• Immunotherapies are expanding therapeutic options, including in frontline regimens.
• Optimizing the sequencing and combination of therapies is crucial for improved outcomes.